The objective of the study was to analyze the relationship of polymorphisms of the angiotensinogen gene with changes in body weight during 3 y of antihypertensive treatment, in a group of young adults with essential hypertension. METHODS: Essential hypertensives, less than 50 y old, never previously treated with antihypertensive drugs and in the absence of diabetes mellitus were included. After the initial evaluation, patients were treated using only non-pharmacological measures (n ¼ 29), b-blockers (n ¼ 40) or angiotensin-converting enzyme inhibitors (n ¼ 66). Resting blood pressure, biochemical profile and body weight at the beginning and yearly were measured. The polymorphism A-6G of the angiotensinogen gene located in the promoter region was analyzed. RESULTS: One-hundred and thirty-five patients were included. Genotypes of the A-6G polymorphism of the AGT gene were in Hardy -Weinberg equilibrium (AA 34, AG 63, GG 38). No significant differences were observed among genotypes in terms of age, body mass index, body weight, systolic or diastolic blood pressure. No significant differences in the genotype distribution or in the allele frequencies were observed, although the A allele was most frequent among the obese subjects. During the 3 y of antihypertensive treatment, there was a trend to increase weight despite the dietary recommendations. The slopes of body weight over time, adjusted by age and baseline BMI, differed significantly among the homozygote genotypes (P ¼ 0.006). The highest were for those with the AA genotype and the lowest for the GG genotype (1.180 AE 0.25 and 7 0.128 AE 0.24 kg=y; P ¼ 0.0001). The influence of the genotype in the changes on body weight remained significant after considering its interaction with the kind of antihypertensive treatment, although among subjects carrying the AA genotype those treated with ACEi showed the least body weight change. Furthermore, A-6G genotypes had the largest influence on weight changes, accounting for 19% of the variance, when age, sex and initial body mass index were included in the model. CONCLUSIONS: In a group of young adult hypertensive subjects, there was a trend to increase weight despite dietary recommendations. Subjects with the AA genotype were those with the largest weight gain, but this effect was modified by the antihypertensive treatment.
Introduction
The renin -angiotensin system has long been recognized as an important regulator of systemic blood pressure and renal electrolyte homeostasis, and local renin -angiotensin systems have also been implicated in pathological changes of organ structure and function by gene expression modulation, growth, fibrosis and inflammatory response. 1 -3 Recently, substantial data have been accumulated in support of the notion that adipose tissue, besides other endocrine functions, also hosts a local renin -angiotensin system, and the angiotensinogen (AGT) gene has been described in adipose tissue. 4 The physiological and pathological role of AGT in adipose cells, however, is not completely understood but in animal models it has been implicated in the pathogenesis of metabolic alterations and hypertension associated obesity. 5 Moreover, elevated adipose AGT gene expression has been described in obese men 6, 7 and a role of AGT, after conversion to angiotensin II, on the growth and development of adipose tissue has also been suggested. 8 Weight loss has been reported after blocking the activity of AGT with the administration of angiotensin converting enzyme inhibitors (ACEi) in several studies conducted in rats and humans. 9, 10 Whether or not the changes in body weight induced by ACEi depend on the genetic background which determine the AGT levels remains to be clarified.
The A-6G polymorphism of the AGT gene in the promoter region has been associated with AGT plasma levels and with mRNA expression in several tissues. 11 Evidence has been published describing an A for G nucleotide substitution of the AGT gene 6 nucleotides upstream from the start site of transcription appears as a functional mutation. 12 The A substitution alters the binding of a nuclear protein resulting in increased gene transcription compatible with increased AGT levels.
The objective of the present study was to observe the changes in body weight linked to the A-6G polymorphism of the AGT gene during a 3 y follow-up period in a group of hypertensives previously untreated with antihypertensive drugs. Furthermore, the interaction between the A-6G polymorphism and the antihypertensive treatment on body weight was analyzed.
Material and methods

Selection of study participants
Patients included in the study were selected from an outpatient clinic over a 5 y period (January 1990 to December 1994). All patients who fulfilled the inclusion criteria were invited to participate, and written consent was requested. The inclusion criteria were the following: (a) diastolic blood pressure ranging from high normal to moderate essential hypertension, defined as being between 85 -114 mmHg (Korotkoff phase V, sitting position) for three visits at one month intervals; (b) from 25 to 50 y of age; (c) absence of cardiovascular events; (d) glomerular filtration rate greater than 60 ml=min=1.73m 2 ; and (e) never previously treated for hypertension. Patients with diabetes mellitus, or fasting glucose in serum > 120 mg=dl were excluded. One-hundred and forty patients were included.
Clinical and analytical procedures
Body weight and height were measured initially. Blood pressure was measured in a quiet environment using a mercury sphygmomanometer with the patient in a sitting position after 5 min of rest, following the recommendations of the British Hypertension Society. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured according to Korotkoff phase I and phase V, respectively.
Blood samples were obtained in the morning after fasting a minimum of 8 h. Serum biochemical profiles and lipids were measured. The glomerular filtration rate (GFR) was estimated by the clearance of endogenous creatinine as expressed in reference to body surface (ml=min=1.73 m 2 ).
After the inclusion, and according to clinical criteria, a non-pharmacological treatment, moderate salt restriction, was recommended. Additionally, a low-energy diet was urged for owerweight subjects. A regimen of antihypertensive drugs based on b-blockers (bB) or ACE was added in subjects with BP > 140=90 mmHg after the initial evaluation. Hydroclorothiazide was added when necessary for maintaining the BP goal of < 135=85 mmHg. From the initial 140 patients, 135 completed the 3 y study, 29 receiving only nonpharmacological treatment, 66 receiving ACEi and 40 receiving bB. During the 3 y of follow-up, body weight and blood pressure were assessed yearly. In each scheduled visit every three months, subjects were interviewed about diet compliance and dietary advice was reinforced.
Analysis of the polymorphisms of the AGT gene
We analyzed the polymorphism A-6G located in the promoter region following the previously described method. 13 We amplified the 3 0 promoter region and exon 1 for oligonucleotides 5 0 -GAG GTC CCA GCG TGA GTG TCG C and 5 0 -CTC AGT TAC ATC CTG AGA GAG ACA AGA CC under standard PCR conditions. Fragments were analyzed by SSCP using water-cooled vertical minigels (10Â10 cm). After adding 9 ml of loading buffer to 1 ml of PCR product, the mix was denatured and was loaded in to 1 ml of gel. The conditions were: 14% acrylamide (29:1 acrylamide:bisacrylamide) in 1ÂTBE buffer at 400 V for 3 h at 15 C. After electrophoresis the gels were silver stained. The SSCP bands were assigned by the direct PCR sequencing of several individuals.
Statistical analysis
To assess mean differences of continuous variables among genotypes, one-way analysis of variance (ANOVA), with the Bonferroni correction for multiple comparisons, and Kruskal -Wallis tests were used. Chi-square tests were conducted to compare differences in percentages and to examine whether the genotype frequencies were in Hardy -Weinberg equilibrium. For each variable, 95% confidence intervals were calculated. The changes of parameters during the follow-up were estimated as the individual specific regression line slope values. Multiple linear regression models with interaction terms were fitted for assessing the factors related to the changes in body weight during the follow-up and the possible interaction of genotypes with antihypertensive treatments. The association between the genotype and body weight was examined using a codominant inheritance model of the alleles. Analyses were done using the Statistical Package for Social Sciences (SPSS, version 9.0) for Windows.
Results
General characteristics of the study population The general characteristics, body weight, body mass index (BMI) and BP values of the patients in each genotype of the Angiotensinogen gene and changes in body weight FJ Chaves et al A-6G polymorphism who completed the study are shown in Table 1 . Genotypes of the A-6G polymorphism of the AGT gene were in Hardy -Weinberg equilibrium (AA 34, AG 63, GG 38). No significant differences were observed among genotypes in terms of age, BMI, body weight, SBP and DBP. Genotype distribution and allele frequencies of A-6G polymorphism in the subjects initially with normal weight, overweight and obese are in Table 2 . No differences in the genotype distribution or in the allele frequencies were observed, although there was a trend to increase the presence of the A allele among the obese subjects.
A-6G polymorphism genotypes and changes in body weight Slope values of the changes in body weight during the follow-up in patients with the genotypes of A-6G polymorphism are shown in Figure 1 . The slopes of body weight over time, adjusted by age and baseline BMI, differed significantly among the homozygote genotypes (P ¼ 0.006); the steepest were those with the AA genotype, and the least steep for those with GG genotype (1.180 AE 0.25 and 7 0.128 AE 0.24 kg=y; P ¼ 0.0001; respectively). The AG values did not differed from those observed in the AA but were significantly higher than those for the GG genotype (0.915 AE 0.19 and 7 0.128 AE 0.24 kg=y; P ¼ 0.001, respectively). Indeed, the presence of the A allele was related to the body weight increase during the 3 y follow-up. The influence of the genotype in the changes in body weight remains significant after considering its interaction with the kind of antihypertensive treatment received (Table 3) . Figure 1 Slope values (kg=y) of the changes of body weight, adjusted by age and baseline BMI, grouped by genotype of the A-6G angiotensinogen gene during a 3 y follow-up period. 
Angiotensinogen gene and changes in body weight FJ Chaves et al
Factors related to the slope of weight were sought using a multiple regression analysis. Genotypes of A-6G were the main factor, accounting for 19% of the variance when age, sex and initial BMI were included in the model.
Antihypertensive treatment and changes in body weight
During the study period, 29 patients did not receive pharmacological treatment, while 66 received ACEi and 40 received bB. At the beginning, the first group was younger and had lower SBP and DBP values than the other two groups. No significant differences were present in terms of BMI among groups. After 3 y of follow-up, an increase in body weight was observed in all three groups, although no significant differences were observed among the groups (non-pharmacological 0.90 AE 0.28 kg=y, bB 0.57 AE 0.25 kg=y and ACEi 0.50 AE 0.18 kg=y; P NS). Among subjects carrying the AA genotype, however, those treated with ACEi showed the least body weight change (Figure 2 ). These results indicate that the antihypertensive treatment modifies the effect of the A-6G polymorphism on changes in body weight (Pvalue for the interaction term ¼ 0.015).
Discussion
The impact on changes in body weight for the A-6G polymorphism of the AGT gene, the type of antihypertensive treatment and their interaction during 3 y were analyzed in a group of young adult hypertensive subjects. There was a trend to weight increase despite the dietary recommendations. Subjects with the AA genotype were those with the major weight gain, but this effect was modified by the antihypertensive treatment, and those treated with ACEi showed the least body weight change.
The characteristics of the study population are representative of those that regularly attend a hypertension clinic, where the percentage of overweight and=or obese subjects is large. In order to reduce potential confounding factors, however, we only included hypertensives less than 50 y old who had never previously been treated with antihypertensive drugs, and in whom diabetes mellitus had been excluded. The large observational period of the study permits the assessment of changes in weight in regular living conditions, when the effect of diet and physical exercise interact with individual metabolic particularities. A limitation of the study is that this long observation time does not permit a close control of calorie intake and=or grade of physical exercise.
The importance of body weight in the prevalence of hypertension has been widely recognized. 14, 15 Changes in body weight, in absence of antihypertensive treatment, accompanied by parallel blood pressure (BP) changes 16 and weight reduction is a main goal in the attempt to control BP. 17 Persistence of obesity is one of the major reasons for the failure of antihypertensive treatment and for refractory hypertension. 18 Moreover, clinical experience indicates the difficulty in maintaining a long-term weight reduction. 19 Consequently, knowing whether or not genetic background influences changes in body weight, and if this influence is modifiable through antihypertensive treatment, can help in the management of hypertension.
The A-6G polymorphism of the AGT gene modifies the AGT levels in both plasma and tissues, a key regulatory element in angiotensin II generation. 11 Since the AGT plasma concentration is close to the Michaelis constant of the enzymatic reaction between AGT and renin, rise or fall of AGT levels leads to a parallel change in the formation of angiotensin II. 20 Adipose tissue development and metabolism have been shown to be regulated by angiotensin II in vivo and in vitro. 21 White adipose tissue and isolated adipocytes contain the components of the renin -angiotensin system. 22 Angiotensin II increases lipogenesis and triglyceride accumulation in 3T3-L1 preadipocytes and human adipocytes, and blocking the angiotensin II with an angiotensin II receptor antagonist causes a decrease in adipocyte size of rats. 23 Recently Massiera and coworkers 24 using transgenic mice were able to demonstrate that white adipose tissue angiotensinogen increases the fat mass. Furthermore, a study with rats showed that fasting for 3 days reduced AGT amounts released per adipose cell to 33% of control animal levels. Refeeding increased adipose tissue AGT release to levels that were 41 -83% higher than those in the control rats. These levels would be expected to have the greatest effects in subjects with the AA genotype who already have greater AGT release. These hypothesis is in agreement with the data in the present study and with those published by Hunt and coworkers. 25 They reported that, under a low energy and low salt diet, weight reduction was also the least in the AA subjects. 25 In the present study, subjects carrying the AA genotype had the highest weight gain, an observation that was consistent with the highest levels of AGT present in subjects with this genetic background.
The impact on body weight of some of the pharmacological treatments used for hypertension has long been recognized. 26 Short-term changes, in terms of days or even Angiotensinogen gene and changes in body weight FJ Chaves et al months, have been described during treatment with diuretics 27 and a-adrenergic blockers, 28 and are mainly due to the effect of drugs in corporal sodium and water content. Longterm changes result from the effect of drugs on the activity of mechanisms implicated in body weight regulation, such as the adrenergic and the renin -angiotensin systems and=or the insulin metabolism. b-Blockers, a class of antihypertensive drugs used for at least three decades, reduces energy expenditure and promotes weight gain. 29, 30 In contrast, studies in rats and humans have reported weight loss by ACEi treatment. 31 -34 This effect in weight loss seems to be mediated by the blockade of angiotensin II generation in adipose tissue. In the present study, subjects treated with ACEi showed the lowest rate of weight gain among those carrying the AA genotype.
Interestingly the increment in body weight among AA subjects was different depending the antihypertensive treatment. Subjects in absence of antihypertensive drugs, probably those with the lower diet compliance, had the highest weight gain. ACEi, which reduces the generation of angiotensin II by blocking the angiotensin converting enzyme, seems to blunt the weight increase observed in the other two groups. Whether this effect can be attributed to a reduction of the activity of the RAS in the adipose tissue, which is more active in subjects with the AA genotype, to an improvement in insulin sensitivity or both, needs to be studied further. Whatever the case, subjects with the AA genotype are those that can obtained the highest benefit in terms of long-term weight gain prevention from treatment with ACEi.
In summary, the A-6G polymorphism of the AGT gene influences the changes in body weight operated during a three year period in a group of young adult hypertensive subjects. The impact of this polymorphism was modified by the administration of ACEi. The present data, and others recently published, have raised questions regarding the role of RAS in weight regulation and in how to transfer this issue to clinical practice. A better understanding of these aspects may permit a more selective approach to the control of body weight during antihypertensive treatment.
